Sweeny Nicole (CIK 1827505) reported 17 SEC Form 4 insider transactions across 1 companies over the past 18 months (most recent 2026-06-11). Recent activity: Sell KALV (59,291 shares), Buy KALV (5,000 shares), Sell KALV (1,489 shares), Buy KALV (6,250 shares), Sell KALV (1,861 shares). Source: SEC Form 4.
| Date | Company | Role | Type | Shares | Value |
|---|---|---|---|---|---|
| 2026-06-11 | KalVista Pharmaceuticals, Inc. (KALV) | Chief Commercial Officer | Sell | 59,291 | $0 |
| 2026-05-27 | KalVista Pharmaceuticals, Inc. (KALV) | Chief Commercial Officer | Buy | 5,000 | $0 |
| 2026-05-27 | KalVista Pharmaceuticals, Inc. (KALV) | Chief Commercial Officer | Sell | 1,489 | $39,872 |
| 2026-05-26 | KalVista Pharmaceuticals, Inc. (KALV) | Chief Commercial Officer | Buy | 6,250 | $0 |
| 2026-05-26 | KalVista Pharmaceuticals, Inc. (KALV) | Chief Commercial Officer | Sell | 1,861 | $49,846 |
| 2026-04-20 | KalVista Pharmaceuticals, Inc. (KALV) | Chief Commercial Officer | Buy | 6,250 | $0 |
| 2026-04-20 | KalVista Pharmaceuticals, Inc. (KALV) | Chief Commercial Officer | Sell | 1,862 | $37,643 |
| 2026-02-24 | KalVista Pharmaceuticals, Inc. (KALV) | Chief Commercial Officer | Buy | 6,250 | $0 |
| 2026-02-24 | KalVista Pharmaceuticals, Inc. (KALV) | Chief Commercial Officer | Buy | 5,000 | $0 |
| 2026-02-24 | KalVista Pharmaceuticals, Inc. (KALV) | Chief Commercial Officer | Sell | 3,975 | $61,891 |
| 2025-12-04 | KalVista Pharmaceuticals, Inc. (KALV) | Chief Commercial Officer | Buy | 6,250 | $0 |
| 2025-12-04 | KalVista Pharmaceuticals, Inc. (KALV) | Chief Commercial Officer | Buy | 5,000 | $0 |
| 2025-12-04 | KalVista Pharmaceuticals, Inc. (KALV) | Chief Commercial Officer | Sell | 3,813 | $51,285 |
| 2025-08-26 | KalVista Pharmaceuticals, Inc. (KALV) | Chief Commercial Officer | Buy | 5,000 | $0 |
| 2025-08-26 | KalVista Pharmaceuticals, Inc. (KALV) | Chief Commercial Officer | Sell | 1,480 | $19,862 |
| 2025-08-25 | KalVista Pharmaceuticals, Inc. (KALV) | Chief Commercial Officer | Buy | 6,250 | $0 |
| 2025-08-25 | KalVista Pharmaceuticals, Inc. (KALV) | Chief Commercial Officer | Sell | 1,864 | $24,642 |
Source: SEC Form 4 filings · as of 2026-06-11